Clinical Trials Sponsored by Aptalis Pharma

Total 8419 results

Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Lupus Nephritis | IgA Nephropathy | Membranous Nephropathy | C3 Glomerulonephritis | Dense Deposit Disease

United States
Apellis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States
Tilman S.A.
Artialis

Completed

Covid-19, Hospitalized, PatIents, Nasafytol

Coronavirus Infection

Belgium
Aptabio Therapeutics, Inc.

Completed

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Diabetes Mellitus, Type 2 | Diabetic Nephropathies | Nephropathy, Diabetic

Bulgaria, Czechia, Hungary, Serbia
Apellis Pharmaceuticals, Inc.

Completed

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD (ASAP II)

Neovascular Age-Related Macular Degeneration

United States, Australia
Apellis Pharmaceuticals, Inc.

Completed

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy (FILLY)

Geographic Atrophy

United States, Australia, New Zealand
Lactalis
Biosearch S.A.

Completed

Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas (JUNGLO)

Growth Failure | Tolerance | Cow Milk Protein Sensitivity

Spain
Saptalis Pharmaceuticals LLC
bioRASI, LLC

Completed

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Scabies

United States
Apellis Pharmaceuticals, Inc.

Recruiting

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States
Aptabio Therapeutics, Inc.

Recruiting

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Contrast Induced Acute Kidney Injury

Korea, Republic of, United States
Apellis Pharmaceuticals, Inc.

Recruiting

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Hemoglobinuria

Malaysia, United States, Czechia, France, Netherlands, Serbia, Spain, Thailand, United Kingdom
Tilman S.A.
Artialis

Completed

Effect and Tolerance of Standardized Exclusive Dry Extracts of Curcuma Longa and of Boswellia Serrata Among People With Hand Joint Discomfort and Dysfunction (CUBO)

Hand Joint Discomfort | Hand Joint Dysfunction

Belgium
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Apellis Pharmaceuticals, Inc.

Terminated

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

United States, Netherlands, Spain, Germany, Japan, Australia, France, Poland, Ukraine, Belgium, Czechia, Ireland, Italy, United Kingdom
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

Geographic Atrophy Secondary to Age-related Macular Degeneration

United States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
Apellis Pharmaceuticals, Inc.

Completed

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States, France, Italy, Netherlands, Israel, Germany, United Kingdom, Spain, Australia, New Zealand, Poland, Brazil, Canada, Czechia
Apellis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

United States, France, Russian Federation, Korea, Republic of, Canada, Germany, Australia, Japan, Spain, Belgium, United Kingdom
Apellis Pharmaceuticals, Inc.

Completed

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Severe Acute Respiratory Syndrome | Coronavirus Infection | Covid-19 | COVID | Acute Respiratory Distress Syndrome | Coronavirus | Ards | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2

United States, Brazil
Apellis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

Geographic Atrophy

United States
Apellis Pharmaceuticals, Inc.

Completed

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. (PADDOCK)

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, New Zealand, Malaysia
Apellis Pharmaceuticals, Inc.

Completed

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

PNH

Serbia, Bulgaria
Apellis Pharmaceuticals, Inc.

Terminated

Pegcetacoplan (APL-2) in Neovascular AMD

Neovascular Age-related Macular Degeneration

United States
Aptabio Therapeutics, Inc.

Completed

Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers

Healthy | Safety

France
Tilman S.A.
Artialis

Completed

Evaluation of FLEXOFYTOL® Versus PLACEBO (COPRA)

Osteoarthritis

Belgium
Amgen
Actavis Inc.

Completed

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

United States, Bulgaria, Australia
Laboratoires Vivacy
Artialis

Completed

Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis (EPIKART)

Knee Osteoarthritis
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Apellis Pharmaceuticals, Inc.

Available

C3G/Primary IC-MPGN EAP

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Pegcetacoplan Long Term Safety and Efficacy Extension Study

PNH

United States, France, Germany, Canada, United Kingdom, Belgium, Hong Kong, Japan, Singapore, Thailand, Russian Federation, Serbia, Australia, Bulgaria, Spain, Malaysia, Korea, Republic of, Colombia, Mexico, Peru, Philippines
Apellis Pharmaceuticals, Inc.

Completed

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Geographic Atrophy

Italy, Germany, United States, Israel, United Kingdom, France, Canada, Czechia, Australia, Spain, Argentina, New Zealand, Poland, Brazil, Puerto Rico
Apellis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, Malaysia, Singapore, Serbia, Peru, Philippines, Colombia, Mexico, Poland
Apellis Pharmaceuticals, Inc.

Completed

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States
Abyss Ingredients
Artialis

Completed

Hydrolyzed Fish Cartilage Effect on Knee Joint Functionality and Discomfort in Adult Population

Knee Discomfort

Belgium
Amgen
Actavis Inc.

Completed

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer (Lilac)

Breast Cancer

Italy, Hungary, Russian Federation, South Africa, Spain, Serbia, Belarus, Ukraine, Chile, Germany, Bulgaria, Greece, Poland, Canada, Brazil, Mexico, Romania, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
Actavis Mid-Atlantic LLC

Completed

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Actinic Keratoses

United States
Actavis Mid-Atlantic LLC

Completed

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Acne Vulgaris

United States, Belize, India
Universitat de Lleida
Lactalis

Recruiting

Glycaemic Index Determination in Oral Nutrition Supplements (BEGINS)

Glucose Metabolism Disorders

Spain
Actavis Mid-Atlantic LLC

Completed

Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo

MILD TO SEVERE ACNE VULGARIS

India
Aptabio Therapeutics, Inc.
Covance

Terminated

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

COVID-19

United States
Alternativa International S.A
Artialis

Completed

Tolerance, Efficacy, revAlidation, Myostim

Anterior Cruciate Ligament Rupture

Belgium
Naturex SA
Artialis; Vizera d.o.o.

Completed

Turmeric Efficacy for Mobility and Joint Function (T-MOTION)

Joint Pain | Knee Discomfort

Croatia, Slovenia
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

Asthma

United States
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Atrophic Vaginitis

United States
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Asthma

United States
Actavis Inc.
Teva Pharmaceuticals USA

Completed

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Rosacea

United States

Clinical Trials Sponsored by Aptalis Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations